Core Viewpoint - The ChiNext Medical Index (970082) closed at 3882.75 points, down 0.63%, with a trading volume of 14.157 billion yuan and a turnover rate of 2.13% on February 6 [1] Group 1: Index Performance - Among the index constituents, 22 stocks rose while 28 stocks fell, with Tigermed leading the gainers at 3.06% and Aier Eye Hospital leading the decliners at 3.82% [1] - The top ten constituents of the ChiNext Medical Index include Aier Eye Hospital (9.18% weight, latest price 11.07, -3.82% change) and Tigermed (8.52% weight, latest price 65.65, +3.06% change) [1] Group 2: Market Capitalization - The total market capitalization of Aier Eye Hospital is approximately 103.232 billion yuan, while Tigermed's market capitalization is around 56.526 billion yuan [1] - Other notable companies include Mindray Medical (229.746 billion yuan) and Kanglong Chemical (55.486 billion yuan) [1] Group 3: Capital Flow - The net outflow of main funds from the ChiNext Medical Index constituents totaled 604 million yuan, while retail investors saw a net inflow of 412 million yuan [1] - The detailed capital flow shows that Tigermed had a net inflow of 14.716 million yuan from main funds, while retail investors experienced a net outflow of 1.41 million yuan [2]

证券日报网讯2月5日，福瑞医科（300049）在互动平台回答投资者提问时表示，公司于2026年1月5日召 开股东会，已审议通过发行H股股票并在香港联合交易所有限公司上市等事项。目前H股正在推进中。 ...

资金流向方面，创业板医疗（970082）指数成份股当日主力资金净流入合计1.45亿元，游资资金净流出 合计3932.48万元，散户资金净流出合计1.06亿元。成份股资金流向详情见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300347 | 泰格医药 | 1.0514 | 10.00% | 8550.73万 | 8.29% | -1.89 Z | -18.28% | | 300896 | 爱美客 | 8599.52万 | 9.08% | -4731.11万 | -4.99% | -3868.41万 | -4.08% | | 300244 | 迪安诊断 | 6648.66万 | 6.13% | -539.06万 | -0.50% | -6109.60万 | -5.63% | | 301293 | 三博脑科 | 5726.39万 | 5.54% | 3264.08万 | 3.16% | -8990.47万 | ...

（文章来源：证券日报） 证券日报网讯 2月2日，福瑞医科在互动平台回答投资者提问时表示，截至2026年1月30日，公司的股东 人数为23107户。 ...

Core Viewpoint - The company's stock price fluctuations are influenced by a combination of market sentiment, industry dynamics, and macroeconomic factors [1] Group 1 - The company stated that its performance data will be included in the 2025 annual report [1] - The 2025 annual report is scheduled to be disclosed on March 25, 2026, at which point specific performance details will be provided [1]

Core Viewpoint - The company is facing unusual losses in the fourth quarter and has been questioned by investors regarding its financial performance and future disclosures [2] Group 1: Financial Performance - The company has received inquiries about the unusual losses reported in the fourth quarter [2] - The company will disclose its annual report for 2025 on March 25, 2026, which will include detailed performance data [2] Group 2: Compliance and Information Disclosure - The company emphasizes its commitment to strict adherence to information disclosure principles to ensure fair access to information for investors [2]

证券日报网讯1月29日，福瑞医科（300049）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东人数为22242户。 ...

Group 1 - The core viewpoint of the article highlights that Furui Medical (300049) has released its earnings forecast for 2025, projecting a significant increase in net profit [1][3] - On January 23, 2026, Furui Medical's stock closed at 73.2 yuan, with a slight increase of 0.87% and a trading volume of 65,000 shares, amounting to a transaction value of 479 million yuan [1] - The company anticipates a net profit attributable to shareholders ranging from 135 million yuan to 164 million yuan for 2025, representing a year-on-year growth of 19.17% to 44.77% [1][3] Group 2 - The earnings forecast indicates that the net profit after deducting non-recurring gains and losses is expected to be between 127 million yuan and 166 million yuan, reflecting a growth of 7.89% to 41.02% year-on-year [1] - The growth in earnings is primarily driven by the increase in revenue and profit from the medical device business of its French subsidiary, along with stable contributions from the company's managed medical strategy in pharmaceuticals and medical services [1][3] - The net inflow of main funds on January 23 was 4.0411 million yuan, while retail investors experienced a net outflow of 7.9863 million yuan [1][3]

Core Viewpoint - Furui Medical Technology Co., Ltd. (福瑞医科) is expected to report a significant increase in net profit for the fiscal year 2025, driven by growth in its medical device business and stable contributions from its managed healthcare strategy [1] Financial Performance - The company's stock closed at 73.2 yuan on January 23, 2026, up 0.87% from the previous trading day, with a total market capitalization of 19.396 billion yuan [1] - The expected net profit attributable to shareholders for 2025 is projected to be between 135 million yuan and 164 million yuan, representing a year-on-year growth of 19.17% to 44.77% [1] - The net profit after deducting non-recurring gains and losses is anticipated to be between 127 million yuan and 166 million yuan, indicating a year-on-year increase of 7.89% to 41.02% [1] Business Drivers - The growth in net profit is primarily attributed to the increase in revenue and profit from the company's French subsidiary's medical device business [1] - The stable contributions from the company's managed healthcare strategy, including pharmaceuticals and medical services, also play a significant role in the expected performance [1] - Non-recurring gains and losses are expected to have a minimal impact on the net profit [1]

Core Viewpoint - The company, Furu Medical (300049.SZ), projects a net profit attributable to shareholders of 135 million to 164 million yuan for 2025, reflecting a year-on-year change of 19.17% to 44.77% [1] Group 1: Financial Projections - For 2025, the medical device business of the French subsidiary is expected to achieve revenue of approximately 1.05 billion to 1.2 billion yuan, with a year-on-year growth of about 13.77% to 30.02% [1] - The net profit from the medical device business is projected to be around 220 million to 260 million yuan, representing a year-on-year increase of approximately 15.48% to 36.47% [1] - The net profit attributable to shareholders from the medical device business is estimated to be about 110 million to 130 million yuan, showing a year-on-year growth of approximately 15.27% to 36.23% [1] Group 2: Other Business Segments - The company plans to adhere to a managed care strategy, with revenue from pharmaceuticals, medical services, and other businesses expected to be around 450 million to 480 million yuan, leading to a net profit attributable to shareholders of approximately 25 million to 34 million yuan [1] - The impact of non-recurring gains and losses on net profit is anticipated to be in the range of -2 million to -8 million yuan for 2025 [1]